News
The last calculating machine designed by Blaise Pascal in private hands is heading to Christie's Paris this November.
As for Seralutinib’s PH-ILD indication, the SERANATA Phase 3 trial will begin site activations in Q4 2025. GOSS has enough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback